Lilly(US:LLY) 智通财经网·2025-08-27 12:48Core Viewpoint - Eli Lilly's drug Verzenio has shown significant progress in late-stage clinical trials, improving overall survival rates for specific breast cancer patients [1] Group 1: Clinical Trial Results - The global Phase III monarchE trial included over 5,500 high-risk early breast cancer patients who are hormone receptor-positive (HR+), HER2-negative, and lymph node-positive [1] - Verzenio, when used in combination with endocrine therapy, demonstrated statistically significant and clinically meaningful improvements in overall survival compared to endocrine therapy alone [1] - The drug also showed sustained benefits in key research metrics such as invasive disease-free survival, which was the primary endpoint of the monarchE trial [1] Group 2: Company Statements and Future Plans - Jacob Van Naarden, head of Eli Lilly's oncology division, emphasized the importance of the data in establishing Verzenio as a standard treatment for high-risk lymph node-positive patients [1] - The company plans to present detailed research findings at an upcoming medical conference and submit the paper for peer review in a prestigious academic journal [1] - Eli Lilly will also engage with major global regulatory agencies to communicate the results [1]